ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune, Successfully Produced Memory-Like NK Cells
August 26, 2021INmune Bio, Inc. (NASDAQ: INMB) announced today that the first patient who received INKmune™ as a potential treatment for high-risk myelodysplastic syndrome (MDS) has successfully shown the NK activation and functional differentiation predicted. -
First COVID-19 patient dosed in Phase II trial of Quellor
November 17, 2020The first patient has been dosed with Quellor in a Phase II clinical trial, evaluating the drug for the treatment of pulmonary complications from COVID-19. -
INmune Bio gets US FDA nod for Phase II trial of Quellor, a sTNF inhibitor for COVID-19 treatment
September 02, 2020Trial to evaluate the efficacy of Quellor to blunt the cytokine storm and decrease the catastrophic complications of COVID-19 infection.
Pharma Sources Insight January 2025
